<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02442310</url>
  </required_header>
  <id_info>
    <org_study_id>LA46-0114</org_study_id>
    <nct_id>NCT02442310</nct_id>
  </id_info>
  <brief_title>Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy Volunteers</brief_title>
  <official_title>Single Dose Crossover Comparative Bioavailability Study of Deferiprone 600 mg Delayed Release Tablets Versus Deferiprone Oral Solution in Healthy Male and Female Volunteers Following a 1200 mg Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ApoPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Algorithme Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ApoPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at the pharmacokinetics of a new formulation of
      deferiprone (deferiprone delayed release tablets) under fed and fasting conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, open-label, randomized, 4-period crossover study of the
      pharmacokinetics of a new formulation of deferiprone, delayed release tablets in twenty
      healthy volunteers. In each study period, blood samples for pharmacokinetics assessment will
      be collected pre-dose and over 24 hours post-dose. Safety will be assessed throughout the
      study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide</measure>
    <time_frame>24-hour interval</time_frame>
    <description>Maximum measured serum concentration. Blood samples will be collected pre-dose and over a 24-hour interval post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for Serum Deferiprone and Deferiprone 3-O-glucuronide</measure>
    <time_frame>24-hour interval</time_frame>
    <description>Time to maximum observed serum concentration. Blood samples will be collected pre-dose and over a 24-hour interval post-dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞for Serum Deferiprone and Deferiprone 3-O-glucuronide</measure>
    <time_frame>24-hour interval</time_frame>
    <description>Area under the serum concentration time curve extrapolated to infinity. Blood samples will be collected pre-dose and over a 24-hour interval post-dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Adverse Events (AEs)</measure>
    <time_frame>Throughout the trial, from the time of the first dose until the last study visit (Day 30 or early termination)</time_frame>
    <description>Number of subjects with AEs, by frequency, severity, time to onset, duration, and relatedness to study product. AEs will include clinically significant changes from baseline in vital signs, 12-lead ECG, physical examinations, and laboratory tests.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Delayed release, fed conditions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 1200 mg dose of deferiprone delayed release tablet formulation administered following a high-fat breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed release, fasting conditions</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 1200 mg dose of deferiprone delayed release tablet formulation, administered following a 10-hour fast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed release half-tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 1200 mg dose of deferiprone delayed release tablet formulation, following a high-fat breakfast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral solution, fasting conditions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single 1200 mg dose of deferiprone oral solution, administered following a 10-hour fast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferiprone delayed release tablet formulation</intervention_name>
    <description>Deferiprone 600 mg delayed release tablet formulation</description>
    <arm_group_label>Delayed release, fed conditions</arm_group_label>
    <arm_group_label>Delayed release, fasting conditions</arm_group_label>
    <arm_group_label>Delayed release half-tablets</arm_group_label>
    <other_name>Deferiprone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferiprone oral solution</intervention_name>
    <description>Deferiprone 100 mg/mL oral solution</description>
    <arm_group_label>Oral solution, fasting conditions</arm_group_label>
    <other_name>Ferriprox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged ≥18 to &lt;50 years

          2. A female volunteer of childbearing potential must agree to use an accepted
             contraceptive regimen from at least 28 days prior to the first administration of the
             study drug until at least 30 days after the last dose of the study drug

          3. A sexually active male must agree that he and/or his female partner will use a
             medically acceptable method of contraception throughout the study and for at least 30
             days following drug administration

          4. Body mass index (BMI) greater than or equal to 18.5 kg/m^2 and below 30.0 kg/m^2

          5. Non- or ex smoker

          6. Clinical laboratory values within the laboratory's stated normal range; if not within
             this range, an abnormal value must be without any clinical significance

          7. Have no clinically significant diseases captured in the medical history, or evidence
             of clinically significant findings on physical examination and/or clinical laboratory
             evaluations (hematology, general biochemistry, coagulation, ECG, and urinalysis)

        Exclusion Criteria:

          1. Pregnant or breastfeeding

          2. Absolute neutrophil count (ANC) &lt; 1.8 x 109/L at screening (no repeat can be
             performed)

          3. History of significant hypersensitivity to deferiprone or any related products
             (including excipients of the formulations) as well as severe hypersensitivity
             reactions (such as angioedema) to any drugs

          4. History or presence of gastrointestinal, liver or kidney disease, or any other
             conditions known to interfere with the absorption, distribution, metabolism or
             excretion of drugs or known to potentiate or predispose to undesired effects

          5. Presence of significant cardiovascular, pulmonary, hematologic, neurological,
             psychiatric, endocrine, immunologic or dermatologic disease

          6. Presence of out-of-range cardiac interval (PR &lt; 110 msec, PR &gt; 220 msec, QRS &lt; 60
             msec, QRS &gt;119 msec and QTcF &gt; 450 msec for males and &gt; 460 msec for females) on the
             screening ECG or other clinically significant ECG abnormalities

          7. Maintenance therapy with any drug or significant history of drug dependency or alcohol
             abuse (&gt; 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)

          8. Any clinically significant illness in the previous 28 days before Day 1 of this study

          9. Serum ferritin value below the normal limit of the reference laboratory at screening

         10. Positive urine screening of alcohol and/or drugs of abuse

         11. Positive results to HIV Ag/Ab Combo, Hepatitis B surface Antigen (HBsAG (B) (hepatitis
             B)) or anti-Hepatitis C Virus (HCV (C)) tests
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Tricta, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ApoPharma Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Algorithme Pharma Inc.</name>
      <address>
        <city>Mount-Royal</city>
        <state>Quebec</state>
        <zip>H3P 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2015</study_first_submitted>
  <study_first_submitted_qc>May 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2015</study_first_posted>
  <results_first_submitted>April 8, 2016</results_first_submitted>
  <results_first_submitted_qc>April 8, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 13, 2016</results_first_posted>
  <last_update_submitted>April 8, 2016</last_update_submitted>
  <last_update_submitted_qc>April 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>deferiprone</keyword>
  <keyword>deferiprone delayed release formulation</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Deferiprone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Healthy Volunteers</title>
          <description>Subjects were randomized to receive the following four treatments in different orders, with a 7-day washout period between treatments:
Deferiprone delayed release tablets under fed conditions.
Deferiprone delayed release tablets under fasting conditions.
Deferiprone delayed release tablets administered as half-tablets, under fed conditions.
Deferiprone oral solution under fasting conditions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Volunteers</title>
          <description>Subjects were randomized to receive the following four treatments in different orders, with a 7-day washout period between treatments:
Deferiprone delayed release tablets under fed conditions.
Deferiprone delayed release tablets under fasting conditions.
Deferiprone delayed release tablets administered as half-tablets, under fed conditions.
Deferiprone oral solution under fasting conditions</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide</title>
        <description>Maximum measured serum concentration. Blood samples will be collected pre-dose and over a 24-hour interval post-dose</description>
        <time_frame>24-hour interval</time_frame>
        <population>The pharmacokinetics population included all subjects who provided evaluable data for at least one of the comparisons of interest</population>
        <group_list>
          <group group_id="O1">
            <title>Delayed Release, Fed Conditions</title>
            <description>A single 1200 mg dose of deferiprone delayed release tablet formulation administered following a high-fat breakfast
Deferiprone delayed release tablet formulation: Deferiprone 600 mg delayed release tablet formulation</description>
          </group>
          <group group_id="O2">
            <title>Delayed Release, Fasting Conditions</title>
            <description>A single 1200 mg dose of deferiprone delayed release tablet formulation, administered following a 10-hour fast
Deferiprone delayed release tablet formulation: Deferiprone 600 mg delayed release tablet formulation</description>
          </group>
          <group group_id="O3">
            <title>Delayed Release Half-tablets</title>
            <description>A single 1200 mg dose of deferiprone delayed release tablet formulation, following a high-fat breakfast
Deferiprone delayed release tablet formulation: Deferiprone 600 mg delayed release tablet formulation</description>
          </group>
          <group group_id="O4">
            <title>Oral Solution, Fasting Conditions</title>
            <description>A single 1200 mg dose of deferiprone oral solution, administered following a 10-hour fast
Deferiprone oral solution: Deferiprone 100 mg/mL oral solution</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Serum Deferiprone and Deferiprone 3-O-glucuronide</title>
          <description>Maximum measured serum concentration. Blood samples will be collected pre-dose and over a 24-hour interval post-dose</description>
          <population>The pharmacokinetics population included all subjects who provided evaluable data for at least one of the comparisons of interest</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax for serum deferiprone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.05" spread="2.85"/>
                    <measurement group_id="O2" value="8.21" spread="2.18"/>
                    <measurement group_id="O3" value="7.43" spread="2.00"/>
                    <measurement group_id="O4" value="16.71" spread="4.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax for serum deferiprone 3-O-glucuronide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.77" spread="3.80"/>
                    <measurement group_id="O2" value="19.27" spread="3.73"/>
                    <measurement group_id="O3" value="15.40" spread="4.33"/>
                    <measurement group_id="O4" value="21.87" spread="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tmax for Serum Deferiprone and Deferiprone 3-O-glucuronide</title>
        <description>Time to maximum observed serum concentration. Blood samples will be collected pre-dose and over a 24-hour interval post-dose</description>
        <time_frame>24-hour interval</time_frame>
        <population>The pharmacokinetics population included all subjects who provided evaluable data for at least one of the comparisons of interest</population>
        <group_list>
          <group group_id="O1">
            <title>Delayed Release, Fed Conditions</title>
            <description>A single 1200 mg dose of deferiprone delayed release tablet formulation administered following a high-fat breakfast
Deferiprone delayed release tablet formulation: Deferiprone 600 mg delayed release tablet formulation</description>
          </group>
          <group group_id="O2">
            <title>Delayed Release, Fasting Conditions</title>
            <description>A single 1200 mg dose of deferiprone delayed release tablet formulation, administered following a 10-hour fast
Deferiprone delayed release tablet formulation: Deferiprone 600 mg delayed release tablet formulation</description>
          </group>
          <group group_id="O3">
            <title>Delayed Release Half-tablets</title>
            <description>A single 1200 mg dose of deferiprone delayed release tablet formulation, following a high-fat breakfast
Deferiprone delayed release tablet formulation: Deferiprone 600 mg delayed release tablet formulation</description>
          </group>
          <group group_id="O4">
            <title>Oral Solution, Fasting Conditions</title>
            <description>A single 1200 mg dose of deferiprone oral solution, administered following a 10-hour fast
Deferiprone oral solution: Deferiprone 100 mg/mL oral solution</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax for Serum Deferiprone and Deferiprone 3-O-glucuronide</title>
          <description>Time to maximum observed serum concentration. Blood samples will be collected pre-dose and over a 24-hour interval post-dose</description>
          <population>The pharmacokinetics population included all subjects who provided evaluable data for at least one of the comparisons of interest</population>
          <units>Hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax for serum deferiprone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" spread="1.77"/>
                    <measurement group_id="O2" value="2.05" spread="0.60"/>
                    <measurement group_id="O3" value="3.49" spread="1.68"/>
                    <measurement group_id="O4" value="0.52" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax for serum deferiprone 3-O-glucuronide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.63" spread="1.48"/>
                    <measurement group_id="O2" value="3.03" spread="0.52"/>
                    <measurement group_id="O3" value="4.75" spread="1.87"/>
                    <measurement group_id="O4" value="1.87" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-∞for Serum Deferiprone and Deferiprone 3-O-glucuronide</title>
        <description>Area under the serum concentration time curve extrapolated to infinity. Blood samples will be collected pre-dose and over a 24-hour interval post-dose</description>
        <time_frame>24-hour interval</time_frame>
        <population>The pharmacokinetics population included all subjects who provided evaluable data for at least one of the comparisons of interest</population>
        <group_list>
          <group group_id="O1">
            <title>Delayed Release, Fed Conditions</title>
            <description>A single 1200 mg dose of deferiprone delayed release tablet formulation administered following a high-fat breakfast
Deferiprone delayed release tablet formulation: Deferiprone 600 mg delayed release tablet formulation</description>
          </group>
          <group group_id="O2">
            <title>Delayed Release, Fasting Conditions</title>
            <description>A single 1200 mg dose of deferiprone delayed release tablet formulation, administered following a 10-hour fast
Deferiprone delayed release tablet formulation: Deferiprone 600 mg delayed release tablet formulation</description>
          </group>
          <group group_id="O3">
            <title>Delayed Release Half-tablets</title>
            <description>A single 1200 mg dose of deferiprone delayed release tablet formulation, following a high-fat breakfast
Deferiprone delayed release tablet formulation: Deferiprone 600 mg delayed release tablet formulation</description>
          </group>
          <group group_id="O4">
            <title>Oral Solution, Fasting Conditions</title>
            <description>A single 1200 mg dose of deferiprone oral solution, administered following a 10-hour fast
Deferiprone oral solution: Deferiprone 100 mg/mL oral solution</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-∞for Serum Deferiprone and Deferiprone 3-O-glucuronide</title>
          <description>Area under the serum concentration time curve extrapolated to infinity. Blood samples will be collected pre-dose and over a 24-hour interval post-dose</description>
          <population>The pharmacokinetics population included all subjects who provided evaluable data for at least one of the comparisons of interest</population>
          <units>ug*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-∞ for serum deferiprone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.70" spread="9.37"/>
                    <measurement group_id="O2" value="35.77" spread="8.74"/>
                    <measurement group_id="O3" value="37.18" spread="9.72"/>
                    <measurement group_id="O4" value="40.61" spread="10.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-∞ for serum deferiprone 3-O-glucuronide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.52" spread="11.47"/>
                    <measurement group_id="O2" value="100.44" spread="13.49"/>
                    <measurement group_id="O3" value="98.23" spread="10.64"/>
                    <measurement group_id="O4" value="101.34" spread="13.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Adverse Events (AEs)</title>
        <description>Number of subjects with AEs, by frequency, severity, time to onset, duration, and relatedness to study product. AEs will include clinically significant changes from baseline in vital signs, 12-lead ECG, physical examinations, and laboratory tests.</description>
        <time_frame>Throughout the trial, from the time of the first dose until the last study visit (Day 30 or early termination)</time_frame>
        <population>The safety population included all subjects who received at least one of the investigational products under study.</population>
        <group_list>
          <group group_id="O1">
            <title>Delayed Release, Fed Conditions</title>
            <description>A single 1200 mg dose of deferiprone delayed release tablet formulation administered following a high-fat breakfast
Deferiprone delayed release tablet formulation: Deferiprone 600 mg delayed release tablet formulation</description>
          </group>
          <group group_id="O2">
            <title>Delayed Release, Fasting Conditions</title>
            <description>A single 1200 mg dose of deferiprone delayed release tablet formulation, administered following a 10-hour fast
Deferiprone delayed release tablet formulation: Deferiprone 600 mg delayed release tablet formulation</description>
          </group>
          <group group_id="O3">
            <title>Delayed Release Half-tablets</title>
            <description>A single 1200 mg dose of deferiprone delayed release tablet formulation, following a high-fat breakfast
Deferiprone delayed release tablet formulation: Deferiprone 600 mg delayed release tablet formulation</description>
          </group>
          <group group_id="O4">
            <title>Oral Solution, Fasting Conditions</title>
            <description>A single 1200 mg dose of deferiprone oral solution, administered following a 10-hour fast
Deferiprone oral solution: Deferiprone 100 mg/mL oral solution</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Adverse Events (AEs)</title>
          <description>Number of subjects with AEs, by frequency, severity, time to onset, duration, and relatedness to study product. AEs will include clinically significant changes from baseline in vital signs, 12-lead ECG, physical examinations, and laboratory tests.</description>
          <population>The safety population included all subjects who received at least one of the investigational products under study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Delayed Release, Fed Conditions</title>
          <description>A single 1200 mg dose of deferiprone delayed release tablet formulation administered following a high-fat breakfast
Deferiprone delayed release tablet formulation: Deferiprone 600 mg delayed release tablet formulation</description>
        </group>
        <group group_id="E2">
          <title>Delayed Release, Fasting Conditions</title>
          <description>A single 1200 mg dose of deferiprone delayed release tablet formulation, administered following a 10-hour fast
Deferiprone delayed release tablet formulation: Deferiprone 600 mg delayed release tablet formulation</description>
        </group>
        <group group_id="E3">
          <title>Delayed Release Half-tablets</title>
          <description>A single 1200 mg dose of deferiprone delayed release tablet formulation, following a high-fat breakfast
Deferiprone delayed release tablet formulation: Deferiprone 600 mg delayed release tablet formulation</description>
        </group>
        <group group_id="E4">
          <title>Oral Solution, Fasting Conditions</title>
          <description>A single 1200 mg dose of deferiprone oral solution, administered following a 10-hour fast
Deferiprone oral solution: Deferiprone 100 mg/mL oral solution</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Paresthesia Mucosal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vessel Puncture Site Haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Face Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Amylase Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor retained title to and the right to publish all documentation, records, raw data, specimens or other work product generated in connection with the trial. Such publications shall not be made without the prior written consent of Sponsor. Neither Party will use the other Party's name in connection with any publication or promotion without the other Party's prior written consent. However, Sponsor has the right to publish appropriate information in order to satisfy regulatory requirements.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Caroline Fradette, PhD</name_or_title>
      <organization>ApoPharma Inc.</organization>
      <phone>416-401-7543</phone>
      <email>cfradett@apopharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

